Atrial Fibrillation Market Size, Share, Opportunities, And Trends By Treatment Type (Pharmacological Treatment, Non-Pharmacological Treatment), By Technology (Radiofrequency, Laser, Cryotherapy, Others), By End-User (Hospitals, Clinics, Others), And By Geography - Forecasts From 2023 To 2028

  • Published : Aug 2023
  • Report Code : KSI061616027
  • Pages : 143

The atrial fibrillation market was valued at US$12.21 billion in 2021 and is expected to grow at a CAGR of 1.32% during the forecast period.

If a person has atrial fibrillation, the usual cycle of electrical impulses in the heart is disturbed. As a result, the heart beats quickly and irregularly and there is insufficient blood flow from the upper chambers (atria) to the lower chambers (ventricles). Many people with A-fib may not experience any symptoms. However, palpitations, a rapid, pounding pulse, shortness of breath, or weakness are the signs of A-fib. Episodes of atrial fibrillation can be sporadic or recurring. Even while A-fib is frequently not a life-threatening condition, it is a serious medical problem that must be appropriately managed to prevent stroke.

Prospects for the atrial fibrillation market to expand

A rise in the prevalence of atrial fibrillation in the elderly population, technological advancements, and a preference for catheter ablation as a cardiac arrhythmia therapy are driving the growth of the atrial fibrillation market share. The lack of skilled professionals and unfavourable preference for pharmacological therapies (drugs) over AF therapeutic devices are predicted to hinder the atrial fibrillation business. However, it is anticipated that innovative medical therapies based on genetics and biotechnology may increase medication demand while decreasing the need for AF devices will drive the market. Additionally, combining drugs and devices improves the results of the therapy of cardiac arrhythmia. As a result, this is predicted to support the atrial fibrillation market growth throughout the anticipated timeframe.

High prevalence of cardiovascular diseases

High blood pressure and obesity are often the main causes of cardiovascular disorders, notably atrial fibrillation. In the Framingham Heart Study, it was discovered that 14% of atrial fibrillation risks were associated with hypertension and that 45% to 50% more chances were associated with obesity. As atrial fibrillation rates rise, the worldwide atrial fibrillation market is anticipated to expand. For instance, atrial fibrillation is the main diagnosis in more than 454,000 hospitalisations in the United States each year, according to information from the Centres for Disease Control and Prevention (CDC) issued in July 2022. Every year, the illness causes over 158,000 fatalities in the US.

Rising utilization of clinical trials

Clinical trials for the treatment are anticipated to fuel the atrial fibrillation market growth. A recent and promising atrial fibrillation treatment approach is combined pharmacological therapy. The combined pharmaceutical therapy demonstrated promising results in clinical tests and helps individuals with atrial fibrillation receive their unmet medical needs. The clinical trials intended to assess the efficacy of a combination therapy employing Multaq and Ranexa were unveiled at the Boston Atrial Fibrillation Symposium. The HARMONY clinical research involved about 150 people with pacemaker implants and non-permanent atrial fibrillation.

Technological Advancements

Technological advancements are changing cardiovascular disease healthcare facilities and services. The increased incidence of cardiovascular illnesses is increasing the need for cutting-edge diagnostic and therapeutic tools that deliver high-quality care. Important atrial fibrillation market participants have successfully created atrial fibrillation therapies, such as the Arctic Front Cardiac Cryoablation Catheter System, which was introduced by Medtronic India in November 2021.

Moreover, the atrial fibrillation market is becoming more competitive due to the introduction of new technologies and product approvals. For instance, Abbott's Amplatzer Amulet Left Atrial Appendage (LAA) Occluder was approved by the FDA in August 2021.

Rise in R&D procedures

The atrial fibrillation market growth will upsurge due to the expanding R&D practises emphasising the developments in the atrial fibrillation sector. For instance, Peerbridge Health and Northwell Health worked together to create their newly established AFib Centre of Excellence in January 2022. Northwell's AFib Centre of Excellence runs a trial programme that focuses on AFib patients with undiagnosed obstructive sleep apnea (OSA) with the help of Peerbridge. The pilot's purpose is to inform cardiologists and sleep experts about the critical link between the two conditions and the most effective methods for treating AFib and OSA concurrently. Developments in atrial fibrillation medicines are thus expected to dominate the atrial fibrillation market.

Increasing product innovations by various market players

The atrial fibrillation market share is anticipated to be boosted by the increasing innovations being done by the major players in the industry to promote the use of devices for condition monitoring. For instance, in July 2022, CardiacSense, a medical-grade, user-friendly watch, was introduced by Xplore Lifestyle, a renowned Medtech supplier in India, in partnership with an Israeli business. The watch tracks and detects abnormal heartbeats that aid in the early identification of potentially deadly cardiac disorders including atrial fibrillation. The watch uses Israeli biosensing technology, which tracks heartbeats using optomechanical sensors, a sophisticated algorithm, an ECG, a PPG, and artefact sensing technology.

The North American atrial fibrillation market is anticipated to grow

North America is predicted to hold the maximum market share due to the availability of cutting-edge products from the leading players. Additionally, a large number of hospitals and healthcare systems deal with the rising prevalence of heart disorders. As a result, businesses are involved in R&D to provide patients with innovative products. Furthermore, the Asia Pacific region is anticipated to have profitable atrial fibrillation market growth over the next years because of the region's strong economic growth and expanding government measures to raise public awareness of chronic illnesses.

Atrial Fibrillation Approvals and Trials

  • In February 2023, Abbott's TactiFlex Ablation Catheter and Sensor Enabled devices achieved approval from both the US FDA and the European Union. These cutting-edge ablation catheters, which are made to treat irregular cardiac rhythms like atrial fibrillation, include a flexible tip and contact force sensing.
  • In September 2022, WATCHMAN FLX received FDA clearance from Boston Scientific Corporation. Additionally, for the post-procedure management of patients with non-valvular atrial fibrillation (NVAF), the WATCHMAN FLX offers a 45-day dual antiplatelet therapy (DAPT) option as an alternative to 45-day oral anticoagulation (OAC) with aspirin.
  • In January 2022, PMDA granted permission to MicroPort CRM for the new Alizea pacemaker line. Cardiologists receive thorough patient reports, timely alarms, improved remote monitoring, and follow-up from Alizea.

Market Key Developments

  • In January 2023, Pfizer started a new initiative in Malaysia to raise awareness of atrial fibrillation's health risks. Cardiologists, neurologists, and other healthcare professionals can use the internet to directly educate patients and caretakers.
  • In July 2022, CardioFocus Inc. highlighted its achievements in the development of advanced pulse field ablation technology for AFib.
  • In April 2022, The EnCompass Clamp, a component of the Isolator Synergy Ablation System, was introduced in the US by AtriCure, Inc. The EnCompass Clamp, which was given FDA 510(k) approval for the ablation of cardiac tissue during cardiac surgery, is intended to improve the effectiveness of concurrent surgical ablations.


  • By Treatment Type
    • Pharmacological Treatment
    • Non-Pharmacological Treatment
  • By Technology
    • Radiofrequency
    • Laser
    • Cryotherapy
    • Others
  • By End-User
    • Hospitals
    • Clinics
    • Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Indonesia
      • Thailand
      • Others


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Pharmacological Treatment

5.3. Non-Pharmacological Treatment


6.1. Introduction

6.2. Radiofrequency

6.3. Laser

6.4. Cryotherapy

6.5. Others


7.1. Introduction

7.2. Hospitals

7.3. Clinics

7.4. Others


8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others


9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix


10.1. AtriCure

10.2. Acutus Medical

10.3. Abbott Vascular

10.4. Kardium

10.5. Medtronic

10.6. Philips

10.7. J&J MedTech

10.8. Affera

10.9. Mayo Clinic

10.10. Cardio Focus


Acutus Medical

Abbott Vascular




J&J MedTech


Mayo Clinic

Cardio Focus